07/22/2026
We're proud to share the publication of a new manuscript supported by our Summit Ascend team highlighting the 12-week Phase 2 results evaluating DD01, a dual GLP-1 and glucagon receptor agonist for MASLD and MASH.
Congratulations to Mazen Noureddin, MD, MHSc, FAASLD, Winston Dunn, and the entire author team on this important publication. We'd also like to recognize the contributions of Beth Brombosz, PhD, our lead medical writer, whose expertise supported the preparation and development of the manuscript.
Additionally, this work was supported by several key members of our broader Summit team, including Rashmee Patil, MD and Dimple Desai, MD, MPH, FAAFP, DABOM, CPI, who are listed as co-authors on this important work.
A special thank you to the Neuraly Inc. team—particularly Dennis To, PhD, Adam C. Bell, PhD, RAC, Jaehee Shin, Daniel Lee, Yen-Huei Lin, and Seulki Lee—for their collaboration and partnership throughout this project.
This publication highlights the value of collaborative scientific partnerships in advancing therapies for patients with chronic liver disease while helping generate evidence that informs future clinical development and patient care.
Read the full publication below:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00130-5/abstract
AstraZeneca US Eli Lilly and Company